An oral anlotinib-capecitabine regimen plus penpulimab as first-line therapy for recurrent/metastatic nasopharyngeal carcinoma (R/M NPC): A multicenter, single-arm, phase 2 clinical trial.
| Publicado en: | Journal of Clinical Oncology Vol. 44; pp. 227 - 247 |
|---|---|
| Autores principales: | , , , , , , , , , , , , , , , , , , , |
| Formato: | Journal Article |
| Publicado: |
American Society of Clinical Oncology
2026 Supplement 19
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=194781349&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 194781349 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 0732183X 20D jtl: Journal of Clinical Oncology issn: 0732183X maglogo: N pubinfo: dt: 2026 Supplement 19 vid: 44 pid: 26892 pub: American Society of Clinical Oncology place: Alexandria, Virginia artinfo: ui: 194781349 10.1200/JCO.2026.44.19_suppl.227 194781349 ppf: 227 ppct: 20 formats: tig: atl: An oral anlotinib-capecitabine regimen plus penpulimab as first-line therapy for recurrent/metastatic nasopharyngeal carcinoma (R/M NPC): A multicenter, single-arm, phase 2 clinical trial. aug: au: Xu, Cheng Qu, Song Liu, Zhigang Yang, Kunyu Huang, Ying Guo, Ling Luo, Dong-Hua Tang, Ling-Long Cai, Qingqing Xia, Yi Zhou, Guan-Qun Zhang, Yuan Su, Fang Wang, Zhiqiang Hong, Xiaohua Li, Jibin Li-Zhi, Liu Tian, Li Li, Haojiang Ma, Jun affil: Sun Yat-sen University Cancer Center sug: pubtype: Academic Journal doctype: Journal Article ougenre: Article ab: language: English refInfo: holdings: @attributes: islocal: N |
|---|